Aytu BioPharma (STU:AY20) Net Issuance of Debt : €-0.14 Mil (TTM As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Aytu BioPharma Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Aytu BioPharma's net issuance of debt for the three months ended in Sep. 2024 was €1.27 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Sep. 2024 was €-0.14 Mil.

Aytu BioPharma Net Issuance of Debt Historical Data

The historical data trend for Aytu BioPharma's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aytu BioPharma Net Issuance of Debt Chart

Aytu BioPharma Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Net Issuance of Debt

Get a 7-Day Free Trial

-14.43

-3.11

-4.94

-2.17

-1.76

Aytu BioPharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Net Issuance of Debt	Get a 7-Day Free Trial															-0.35	-0.19	0.49	-1.71	1.27

Aytu BioPharma Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.14 Mil.

Aytu BioPharma Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Aytu BioPharma's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Aytu BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aytu BioPharma Inc (STU:AY20) » Definitions » Net Issuance of Debt

Comparable Companies

Traded in Other Exchanges

AYTU:USA 0A8M:UK

Address

7900 East Union Avenue, Suite 920, Denver, CO, USA, 80237

Website

https://www.aytubio.com

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

Aytu BioPharma Headlines

No Headlines